WILMINGTON, Mass., Sept. 15, 2014 /PRNewswire/ -- Implant
Sciences Corporation (OTCQB: IMSC), a high technology supplier of
systems and sensors for homeland security and defense markets,
today announced its CEO Glenn D.
Bolduc is scheduled to present at the National Investment
Banking Association's (NIBA) 132nd Investment Conference
on Tuesday, September 16, 2014 at
11:55 am ET. The conference takes
place in New York City on
September 15th through
17th at the Roosevelt Hotel.
This conference closely follows a string of high-profile
international sales as well as the Company's flagship product's,
the QS-B220 explosives trace detector, addition to the
Transportation Security Administration's (TSA) Qualified Products
List (QPL). Mr. Bolduc's presentation will center on the growing
momentum of Implant Sciences, the impact of these recent events,
and the future of the Company.
About NIBA
Since 1982, The National Investment Banking
Association (NIBA) has been a not-for-profit association for
national, regional and independent broker dealers, investment
banking firms, investment advisors, and related capital market
service providers. NIBA has over 30 years of experience hosting
conferences featuring public and private micro-cap and small-cap
companies. During those 30 years NIBA Members have completed over a
1000 deals that have raised over $10 billion
dollars for emerging growth companies. The NIBA
Membership represents over 60+ services centered around micro-cap
and small-cap companies.
About Implant Sciences
Implant Sciences is a
leader in developing and manufacturing advanced detection
capabilities to counter and eliminate the ever-evolving threats
from explosives and drugs. The Company's team of dedicated trace
detection experts has developed proprietary technologies used in
its commercial products, thousands of which have been sold across
more than 50 countries worldwide. Implant Sciences is only the
third manufacturer, and the sole American-owned company, to
currently have an ETD system named as a Qualified Product by the US
Transportation Security Administration. The Company's ETDs have
received approvals and certifications from several international
regulatory agencies including the TSA in the U.S., STAC in
France, the German Ministry of the
Interior, and the Ministry of Public Safety in China. It also received a GSN 2013 Homeland
Security Award for "Best Explosives Detection Solution". All
Implant Sciences products are recognized as Qualified
Anti-Terrorism Technologies by the Department of Homeland Security.
For further details on the Company and its products, please visit
the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain
certain "forward-looking statements," as that term is defined in
the Private Securities Litigation Reform Act of 1995. Such
statements are based on management's current expectations and are
subject to risks and uncertainties that could cause the Company's
actual results to differ materially from the forward-looking
statements. Such risks and uncertainties include, but are not
limited to, the risks that we will be required to repay all of our
indebtedness to our secured lenders by March
31, 2015; if we are unable to satisfy our obligations and to
raise additional capital to fund operations, our secured lenders
may seize our assets and our business may fail; we continue to
incur substantial operating losses and may never be profitable; our
independent registered public accounting firm has expressed
substantial doubt as to our ability to continue as a going concern;
there is no guaranty that the Transportation Security
Administration (TSA) or any other U.S. or foreign government and
law enforcement agencies or commercial consumers will purchase any
of our explosives detection products or that any new products we
may develop will be accepted by the TSA or by such other
governments, agencies or consumers; economic, political and other
risks associated with international sales and operations could
adversely affect our sales; liability claims related to our
products or our handling of hazardous materials could damage our
reputation and have a material adverse effect on our financial
results; our business is subject to intense competition; our
markets are subject to rapid technology change and our success will
depend on our ability to develop and introduce new products; we may
not be able to retain our management and key employees or identify,
hire and retain additional personnel as needed; we may not be able
to enforce our patent and other intellectual property rights or
operate without infringing on the proprietary rights of others; and
other risks and uncertainties described in our filings with the
Securities and Exchange Commission, including our most recent Forms
10-K, 10-Q and 8-K. Such statements are based on management's
current expectations and assumptions which could differ materially
from the forward-looking statements.
Contact:
Implant Sciences Corporation
Company Contact:
Glenn Bolduc, CEO
978-752-1700
or
Investor Contact:
Laurel Moody
646-810-0608
SOURCE Implant Sciences Corporation